FDG PET/CT基线代谢肿瘤负荷预测晚期NSCLC免疫检查点抑制剂治疗结局
多因素分析显示TMTV>75 cm³和dNLR>3与更短OS及缺乏DCB相关,而肿瘤SUVmax与PFS或OS无关联。基线肿瘤负荷和炎症状态可共同用于改善合适候选者的筛选。
要点
- TMTV>75 cm³与更短OS及缺乏DCB独立相关。
- dNLR>3与更短OS、PFS及缺乏DCB相关。
- 肿瘤SUVmax与PFS或OS无关联。
核心结论
- 基线FDG PET/CT的TMTV和炎症状态dNLR与晚期NSCLC患者ICI治疗的不良OS及缺乏DCB相关,而肿瘤SUVmax无此关联。
- TMTV和dNLR可能共同用于改善ICI合适候选者的筛选。
研究设计与样本
- 患者于2013年7月至2018年9月间在ICI启动前接受基线FDG PET/CT。
- 评估临床、生物学(包括dNLR)、病理及PET参数(肿瘤SUVmax、TMTV)。
- 采用Cox模型建立PFS和OS的多因素预测模型,采用逻辑回归检验生物标志物与DCB的关联。
主要发现
- 多因素分析中,TMTV>75 cm³与更短OS相关(HR 2.5,95%CI 1.3-4.7),并与缺乏DCB相关(OR 0.3,95%CI 0.1-0.9)。
- dNLR>3与更短OS相关(HR 3.3,95%CI 1.6-6.4),并与缺乏DCB相关(OR 0.4,95%CI 0.2-0.9)。
- dNLR是PFS的显著预后因素(HR 1.9,95%CI 1.1-3.3),贫血亦与PFS相关(HR 1.9,95%CI 1.2-3.8)。
- 肿瘤SUVmax与PFS或OS之间未观察到关联。
关键数值与推荐
- TMTV阈值75 cm³用于OS和DCB的多因素分析。
- dNLR阈值3用于OS、PFS和DCB的多因素分析。
临床怎么用
- 在晚期NSCLC患者启动ICI治疗前,可考虑利用基线FDG PET/CT测量TMTV并结合dNLR评估预后风险。
- TMTV>75 cm³或dNLR>3提示OS较短及缺乏DCB可能性较高,可能辅助筛选ICI候选者。
- 肿瘤SUVmax不宜单独用于预测ICI治疗的PFS或OS。
局限性
- 回顾性单中心研究设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We aimed to evaluate if imaging biomarkers on FDG PET are associated with clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs). METHODS: In this retrospective monocentric study, we included 109 patients with advanced NSCLC who underwent baseline FDG PET/CT before ICI initiation between July 2013 and September 2018. Clinical, biological (including dNLR = neutrophils/[leukocytes minus neutrophils]), pathological and PET parameters (tumor SUVmax, total metabolic tumor volume [TMTV]) were evaluated. A multivariate prediction model was developed using Cox models for progression-free survival (PFS) and overall survival (OS). The association between biomarkers on FDG PET/CT and disease clinical benefit (DCB) was tested using logistic regression. RESULTS: Eighty patients were eligible. Median follow-up was 11.6 months (95%CI 7.7-15.5). Sixty-four and 52 patients experienced progression and death, respectively. DCB was 40%. In multivariate analyses, TMTV > 75 cm3 and dNLR > 3 were associated with shorter OS (HR 2.5, 95%CI 1.3-4.7 and HR 3.3, 95%CI 1.6-6.4) and absence of DCB (OR 0.3, 95%CI 0.1-0.9 and OR 0.4, 95%CI 0.2-0.9). Unlike TMTV, dNLR was a significant prognostic factor for PFS (HR 1.9, 95%CI 1.1-3.3) along with anemia (HR 1.9, 95%CI 1.2-3.8). No association was observed between tumor SUVmax and PFS or OS. CONCLUSION: Baseline tumor burden (TMTV) on FDG PET/CT scans and inflammatory status (dNLR) were associated with poor OS and absence of DCB for ICI treatment in advanced NSCLC patients, unlike tumor SUVmax, and may be used together to improve the selection of appropriate candidates.
引用
- Seban RD, Mezquita L, Berenbaum A, et al. Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors. Eur J Nucl Med Mol Imaging. 2019. PMID: 31754795. doi:10.1007/s00259-019-04615-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。